



(11) **EP 1 949 903 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/522 ^(2006.01) **A61K 31/498** ^(2006.01)
A61K 31/53 ^(2006.01) **A61K 31/42** ^(2006.01)
A61K 31/519 ^(2006.01) **A61K 31/4709** ^(2006.01)

(48) Corrigendum issued on:
23.05.2012 Bulletin 2012/21

(86) International application number:
PCT/ES2006/000564

(45) Date of publication and mention
of the grant of the patent:
18.04.2012 Bulletin 2012/16

(87) International publication number:
WO 2007/045705 (26.04.2007 Gazette 2007/17)

(21) Application number: **06830873.3**

(22) Date of filing: **10.10.2006**

(54) **SELECTIVE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AURICULAR FIBRILLATION**

SELEKTIVE A2A-REZEPTORANTAGONISTEN ZUR BEHANDLUNG VON VORHOFFLIMMERN

ANTAGONISTES SÉLECTIFS DU RECEPTEUR A2A POUR LE TRAITEMENT DE LA FIBRILLATION AURICULAIRE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(74) Representative: **ABG Patentes, S.L.**
Avenida de Burgos 16D
Edificio Euromor
28036 Madrid (ES)

(30) Priority: **14.10.2005 ES 200502545**

(56) References cited:
EP-A1- 0 544 444 WO-A1-01/40245
WO-A1-02/055524 US-A- 4 772 607
US-A- 5 998 387 US-A1- 2003 022 890
US-A1- 2004 192 698

(43) Date of publication of application:
30.07.2008 Bulletin 2008/31

(73) Proprietor: **Proyecto de Biomedicina Cima, S.L.**
31008 Pamplona - Navarra (ES)

(72) Inventors:
• **FRANCO FERNÁNDEZ, Rafael**
E-08028 Barcelona (ES)
• **CIRUELA ALFÉREZ, Francisco**
E-08328 Barcelona (ES)
• **LLUÍS BISET, Carmen**
E-08029 Barcelona (ES)
• **MÜLLER, Christa**
53113 Bonn (DE)
• **CINCA CUSCULLOLA, Joan**
E-08017 Barcelona (ES)
• **HOVE-MADSEN, Leif**
E-08391 Tiana (Barcelona) (ES)

- **BERTOLET B D ET AL: "Myocardial infarction related atrial fibrillation: role of endogenous adenosine" HEART, BMJ, LONDON, GB, vol. 78, 1 January 1997 (1997-01-01), pages 88-90, XP003014314 ISSN: 1355-6037**
- **DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2002 (2002-01), KULISEVSKY JAIME ET AL: "A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease" XP002518252 Database accession no. PREV200200217042 & CLINICAL NEUROPHARMACOLOGY, vol. 25, no. 1, January 2002 (2002-01), pages 25-31, ISSN: 0362-5664**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 949 903 B8

- YASUI KOZO ET AL: "Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism" JOURNAL OF LEUKOCYTE BIOLOGY, vol. 67, no. 4, April 2000 (2000-04), pages 529-535, XP002518251 ISSN: 0741-5400
- BERTOLET B.D. ET AL.: 'Myocardial infarction related atrial fibrillation: role of endogenous adenosine' HEART vol. 78, 1997, pages 88 - 90, XP003014314

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification